Free Trial

Analysts Set DocGo Inc. (NASDAQ:DCGO) Price Target at $4.89

DocGo logo with Medical background

Shares of DocGo Inc. (NASDAQ:DCGO - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $4.89.

Several analysts recently issued reports on DCGO shares. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 price objective on shares of DocGo in a report on Tuesday, April 8th. Stifel Nicolaus dropped their price objective on DocGo from $6.50 to $5.50 and set a "buy" rating on the stock in a research note on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft downgraded DocGo from a "buy" rating to a "hold" rating and decreased their target price for the company from $5.00 to $2.85 in a research note on Friday, February 28th.

Check Out Our Latest Analysis on DocGo

Institutional Trading of DocGo

Several institutional investors have recently modified their holdings of the company. Summit Investment Advisors Inc. increased its holdings in DocGo by 38.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 10,639 shares of the company's stock valued at $45,000 after buying an additional 2,968 shares during the period. Prudential Financial Inc. bought a new stake in DocGo in the fourth quarter valued at about $55,000. Royce & Associates LP bought a new position in DocGo during the fourth quarter worth about $64,000. Boothbay Fund Management LLC boosted its holdings in DocGo by 154.9% during the fourth quarter. Boothbay Fund Management LLC now owns 27,445 shares of the company's stock valued at $116,000 after purchasing an additional 77,445 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of DocGo by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,641 shares of the company's stock valued at $121,000 after purchasing an additional 9,425 shares during the period. Institutional investors and hedge funds own 56.44% of the company's stock.

DocGo Price Performance

DCGO traded up $0.06 on Friday, hitting $2.17. The company had a trading volume of 627,913 shares, compared to its average volume of 748,137. DocGo has a 1-year low of $2.02 and a 1-year high of $5.68. The company's fifty day moving average price is $3.10 and its 200 day moving average price is $3.78. The stock has a market cap of $220.79 million, a price-to-earnings ratio of 7.73, a price-to-earnings-growth ratio of 14.16 and a beta of 1.12.

DocGo Company Profile

(Get Free Report

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.

Read More

Analyst Recommendations for DocGo (NASDAQ:DCGO)

Should You Invest $1,000 in DocGo Right Now?

Before you consider DocGo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.

While DocGo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping
After Stellar Earnings, Is TSMC the Next Chip Leader?
Palantir’s Big Week Reveals a Rare Growth Story in a Shaky Market

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines